Could low blood protein make a common antibiotic riskier after surgery?
NCT ID NCT07773584
First seen Aug 19, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This observational study looks at whether low albumin levels (hypoalbuminemia) increase the risk of bleeding problems (coagulopathy) in patients who receive the antibiotic cefoperazone/sulbactam after surgery. Researchers will follow coagulation tests in about 108 post-operative patients to see how often bleeding issues occur and what other factors, like kidney function or dose, might contribute. The goal is to better understand and potentially prevent this side effect.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cefoperazone/sulbactam (an antibiotic combination)
- What this could lead to
- If low albumin is confirmed as a risk factor, doctors could monitor and manage it to reduce bleeding complications in surgical patients on this antibiotic.
- What could go wrong
- This is an observational study, so it can only show associations, not cause and effect. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 108 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2027
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be enrolled from the Department Of General Surgery at Shaikh Zayed Hospital, Lahore who fulfill the eligibility criteria.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients \>= 18 years * Post-operative surgical patients * Receiving cefoperazone/sulbactam therapy for at least 72 hours. * Willing to give informed consent Exclusion Criteria: * Chronic liver disease * History of any inherited coagulation disorder * On anticoagulant therapy * Any massive blood loss requiring blood transfusion * Patients who have been given Vitamin K prior to the start of cefoperazone/sulbactam therapy * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypoalbuminemia and cefoperazone/sulbactam induced coagulopathy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.